Petershill Partners (LON:PHLL – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Monday . The company traded as high as GBX 229 ($3.07) and last traded at GBX 224 ($3.00), with a volume of 8545461 shares. The stock had previously closed at GBX 225.50 ($3.02).
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on PHLL. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 245 ($3.28) price objective on shares of Petershill Partners in a research report on Thursday, September 5th. Berenberg Bank reissued a “buy” rating and issued a GBX 235 ($3.15) price objective on shares of Petershill Partners in a research note on Wednesday, September 18th.
Read Our Latest Stock Analysis on PHLL
Petershill Partners Stock Performance
Petershill Partners Increases Dividend
The business also recently disclosed a dividend, which will be paid on Thursday, October 31st. Stockholders of record on Thursday, September 26th will be paid a $0.14 dividend. This represents a dividend yield of 4.83%. The ex-dividend date of this dividend is Thursday, September 26th. This is a boost from Petershill Partners’s previous dividend of $0.10. Petershill Partners’s dividend payout ratio (DPR) is presently 5,454.55%.
Petershill Partners Company Profile
Petershill Partners PLC operates as a general partner solutions investment firm. It provides capital and strategic support to asset managers through minority stake acquisitions. The company was formerly known as Delta Epsilon plc and changed its name to Petershill Partners PLC in September 2, 2021. The company was founded in 2007 and is based in London, the United Kingdom.
Read More
- Five stocks we like better than Petershill Partners
- Insider Buying Explained: What Investors Need to Know
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- How to Invest in Blue Chip Stocks
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- Retail Stocks Investing, Explained
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Petershill Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petershill Partners and related companies with MarketBeat.com's FREE daily email newsletter.